BR112021021117A2 - Compostos e suas composições farmacêuticas para o tratamento de doenças renais - Google Patents
Compostos e suas composições farmacêuticas para o tratamento de doenças renaisInfo
- Publication number
- BR112021021117A2 BR112021021117A2 BR112021021117A BR112021021117A BR112021021117A2 BR 112021021117 A2 BR112021021117 A2 BR 112021021117A2 BR 112021021117 A BR112021021117 A BR 112021021117A BR 112021021117 A BR112021021117 A BR 112021021117A BR 112021021117 A2 BR112021021117 A2 BR 112021021117A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- compounds
- pharmaceutical compositions
- kidney diseases
- prophylaxis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1905711.6A GB201905711D0 (en) | 2019-04-24 | 2019-04-24 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| PCT/EP2020/061083 WO2020216740A1 (en) | 2019-04-24 | 2020-04-21 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021021117A2 true BR112021021117A2 (pt) | 2021-12-14 |
Family
ID=66810218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021117A BR112021021117A2 (pt) | 2019-04-24 | 2020-04-21 | Compostos e suas composições farmacêuticas para o tratamento de doenças renais |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12383544B2 (https=) |
| EP (1) | EP3958863B1 (https=) |
| JP (1) | JP7543304B2 (https=) |
| KR (1) | KR20220004111A (https=) |
| CN (1) | CN113727711A (https=) |
| AU (1) | AU2020263869A1 (https=) |
| BR (1) | BR112021021117A2 (https=) |
| CA (1) | CA3137445A1 (https=) |
| ES (1) | ES2982398T3 (https=) |
| GB (1) | GB201905711D0 (https=) |
| IL (1) | IL287392A (https=) |
| MA (1) | MA55752A (https=) |
| MX (1) | MX2021012544A (https=) |
| PH (1) | PH12021552680A1 (https=) |
| SG (1) | SG11202111739VA (https=) |
| WO (1) | WO2020216740A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025096453A1 (en) * | 2023-10-30 | 2025-05-08 | Vertex Pharmaceuticals Incorporated | Compounds for the treatment of kidney disease |
| WO2025121320A1 (ja) * | 2023-12-04 | 2025-06-12 | 国立大学法人山口大学 | 多発性嚢胞腎の予防又は治療剤 |
| TW202547458A (zh) * | 2024-03-26 | 2025-12-16 | 香港商禮邦醫藥（香港）有限公司 | 用於治療體染色體顯性多囊性腎病之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362031B2 (en) * | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| EP2464354B1 (en) * | 2009-08-10 | 2015-04-01 | The Regents of The University of California | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| TWI704919B (zh) * | 2012-05-31 | 2020-09-21 | 日商大塚製藥股份有限公司 | 用於預防及/或治療多囊性腎臟病之藥物 |
| US10174012B2 (en) * | 2014-11-04 | 2019-01-08 | The University Of Kansas | LKB1-AMPK activators for therapeutic use in polycystic kidney disease |
| US10130622B2 (en) * | 2015-10-09 | 2018-11-20 | Abbvie S.Á.R.L. | Compounds for treatment of cystic fibrosis |
| AU2016333855A1 (en) | 2015-10-09 | 2018-04-26 | AbbVie S.à.r.l. | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use |
| RU2724345C2 (ru) | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
| WO2018237174A2 (en) * | 2017-06-21 | 2018-12-27 | The Johns Hopkins University | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR THE TREATMENT OF DOMINANT AUTOMATIC RENAL POLYKYSTOSIS |
-
2019
- 2019-04-24 GB GBGB1905711.6A patent/GB201905711D0/en not_active Ceased
-
2020
- 2020-04-21 CN CN202080030725.9A patent/CN113727711A/zh active Pending
- 2020-04-21 PH PH1/2021/552680A patent/PH12021552680A1/en unknown
- 2020-04-21 AU AU2020263869A patent/AU2020263869A1/en not_active Abandoned
- 2020-04-21 US US17/605,623 patent/US12383544B2/en active Active
- 2020-04-21 SG SG11202111739VA patent/SG11202111739VA/en unknown
- 2020-04-21 EP EP20721493.3A patent/EP3958863B1/en active Active
- 2020-04-21 ES ES20721493T patent/ES2982398T3/es active Active
- 2020-04-21 KR KR1020217038004A patent/KR20220004111A/ko not_active Withdrawn
- 2020-04-21 CA CA3137445A patent/CA3137445A1/en active Pending
- 2020-04-21 MX MX2021012544A patent/MX2021012544A/es unknown
- 2020-04-21 BR BR112021021117A patent/BR112021021117A2/pt not_active Application Discontinuation
- 2020-04-21 MA MA055752A patent/MA55752A/fr unknown
- 2020-04-21 JP JP2021562854A patent/JP7543304B2/ja active Active
- 2020-04-21 WO PCT/EP2020/061083 patent/WO2020216740A1/en not_active Ceased
-
2021
- 2021-10-19 IL IL287392A patent/IL287392A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL287392A (en) | 2021-12-01 |
| SG11202111739VA (en) | 2021-11-29 |
| MX2021012544A (es) | 2021-11-12 |
| MA55752A (fr) | 2022-03-02 |
| AU2020263869A1 (en) | 2021-12-23 |
| KR20220004111A (ko) | 2022-01-11 |
| GB201905711D0 (en) | 2019-06-05 |
| EP3958863B1 (en) | 2024-07-03 |
| CA3137445A1 (en) | 2020-10-29 |
| WO2020216740A1 (en) | 2020-10-29 |
| CN113727711A (zh) | 2021-11-30 |
| US20220202802A1 (en) | 2022-06-30 |
| EP3958863C0 (en) | 2024-07-03 |
| PH12021552680A1 (en) | 2022-07-04 |
| JP7543304B2 (ja) | 2024-09-02 |
| US12383544B2 (en) | 2025-08-12 |
| EP3958863A1 (en) | 2022-03-02 |
| ES2982398T3 (es) | 2024-10-16 |
| JP2022529814A (ja) | 2022-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014008045A2 (pt) | benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112014018879A8 (pt) | Composto e composição farmacêutica e combinação compreendendo dito composto | |
| BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
| MX385718B (es) | Compuestos moduladores de fxr (nr1h4). | |
| BR112015027527A2 (pt) | intensificador de inibidores do homólogo zeste 2 | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| BR112021021117A2 (pt) | Compostos e suas composições farmacêuticas para o tratamento de doenças renais | |
| MA37866A1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| BR112017023740A2 (pt) | ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida? | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| BR112022024045A2 (pt) | Moduladores il-17a | |
| BR112016023554A2 (pt) | novos compostos macrocíclicos | |
| MA39171A1 (fr) | Dérivés d'hydroxy formamide et leur utilisation | |
| SA523451905B1 (ar) | Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات | |
| SA521431279B1 (ar) | D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| BR112015004523A2 (pt) | compostos de tetraciclina | |
| BR112017022757A2 (pt) | derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap) | |
| BR112017000826A2 (pt) | novas 2,5-piridinas substituídas. | |
| BR112021019099A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| MA40149A1 (fr) | Dérivés de nucléoside 4'-vinyle substitués utiles en tant qu'inhibiteurs de la réplication due l'arn du virus respiratoire syncytial | |
| BR112015026055A2 (pt) | novos compostos de pirimidina condensados substituídos | |
| BR112015019919A2 (pt) | compostos bicíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |